What Happened?
Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 2.8% in the morning session after its recently acquired subsidiary, Masimo, received U.S. Food and Drug Administration (FDA) clearance for an artificial intelligence-enabled feature on its wearable patient monitoring platform.
The approved feature is designed to detect opioid-induced respiratory depression, a serious medical condition. Danaher officially acquired Masimo in June 2026, a move that expanded its footprint in specialty diagnostics and patient-monitoring technologies. Investors reacted favorably to the regulatory clearance for the new AI-powered system, viewing it as a positive development for the newly integrated business.
The shares were trading at $194.71, up 3.1% from the previous close.
Is now the time to buy Danaher? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Danaher’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 8 months ago when the stock gained 7.5% on the news that the company reported third-quarter 2025 financial results that surpassed analyst expectations for revenue and profit.
Danaher announced revenue grew 4.4% from the previous year to $6.05 billion, ahead of the $6.01 billion consensus estimate. The company’s adjusted earnings per share also came in strong at $1.89, higher than the anticipated $1.72.
The report was not entirely positive, however, as management's revenue guidance for the upcoming fourth quarter of $6.70 billion came in below Wall Street's expectations of $7.03 billion. Despite the weaker outlook, investors appeared to focus on the current quarter's outperformance, sending the stock higher.
Danaher is down 15.5% since the beginning of the year, and at $194.71 per share, it is trading 19.6% below its 52-week high of $242.05 from January 2026. Investors who bought $1,000 worth of Danaher’s shares 5 years ago would now be looking at only $730.44.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.